Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Immucell (ICCC) over the last 3 years, with Q3 2025 value amounting to $264832.0.

  • Immucell's Other Accumulated Expenses fell 2958.69% to $264832.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $264832.0, marking a year-over-year decrease of 2958.69%. This contributed to the annual value of $234552.0 for FY2024, which is 2168.46% up from last year.
  • Latest data reveals that Immucell reported Other Accumulated Expenses of $264832.0 as of Q3 2025, which was down 2958.69% from $147790.0 recorded in Q2 2025.
  • Immucell's Other Accumulated Expenses' 5-year high stood at $376112.0 during Q3 2024, with a 5-year trough of $131539.0 in Q1 2025.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $213653.0 (2023), whereas its average is $224596.5.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 2168.46% in 2024, then crashed by 2958.69% in 2025.
  • Immucell's Other Accumulated Expenses (Quarter) stood at $192754.0 in 2023, then grew by 21.68% to $234552.0 in 2024, then grew by 12.91% to $264832.0 in 2025.
  • Its last three reported values are $264832.0 in Q3 2025, $147790.0 for Q2 2025, and $131539.0 during Q1 2025.